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THE effect of  various phospholipase A2 and protein
kinase inhibitors on the arachidonic acid liberation
in  bovine  platelets  induced  by  the  protein  kinase
activator 12-O-tetradecanoylphorbol–13-acetate (TPA)
was studied. TPA stimulates arachidonic acid release
mainly by activating group IV cytosolic PLA2 (cPLA2 ),
since inhibitors  of  this  enzyme  markedly  inhibited
arachidonic acid formation. However, group VI Ca2+-
independent PLA2 (iPLA2 ) seems to contribute to the
arachidonic  acid  liberation  too,  since  the relatively
specific  iPLA2 inhibitor  bromoenol  lactone  (BEL)
decreased  arachidonic  acid  generation in  part.  The
pronounced  inhibition  of  the  TPA-induced  arachi-
donic  acid  release  by  the  protein  kinase  C  (PKC)
inhibitors GF 109203X and Ro 31–82220, respectively,
and  by  the  p38  MAP  kinase  inhibitor  SB  202190
suggests  that  the  activation  of  the  PLA2s  by  TPA  is
mediated via PKC and p38 MAP kinase.
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Introduction
The stimulation of cells by diverse agonists leads to
the  liberation  of  arachidonic  acid  from  membrane
phospholipids. Arachidonic acid can be metabolized
through  the  cyclooxygenase  or  lipoxygenase  path-
ways  to  form  the  eicosanoids,  including  prosta-
glandins and leukotrienes. These are important media-
tors  of  acute  inflammatory  processes.  There  is
substantial evidence that this arachidonic acid release
is mediated by the Ca2+-sensitive group IV cytosolic
phospholipase A2 (cPLA2 ).1–4
The  activity  of  the  cPLA2,  which  is  present  in
many  mammalian  cells,  can  be  regulated  by  two
important mechanisms. The first appears to be a rise
in the intracellular Ca2+ concentration, which causes
translocation  of  the  cPLA2 from  the  cytosol  to  the
internal membranes where it  binds through a Ca2+-
dependent  lipid  binding  domain. A  second  mecha-
nism of regulation of cPLA2 is its phosphorylation by
protein  kinases.1,4 So  the  phorbol  ester
12-O-tetradecanoylphorbol–13-acetate  (TPA),  which
is  known  to  exhibit  its  physiological  activities  via
stimulation of protein kinases,5 induced an increase
in phosphorylation and catalytic activity of cPLA2 as
well  as  arachidonic  acid  release  in  macrophages,
neutrophiles,  keratinocytes  and  glomerular  mesan-
gial cells.6–10
We  have  previously  reported  that TPA  is  able  to
stimulate  the  liberation  of  arachidonic  acid  also  in
platelets.11 In  these  cells  different  protein  kinases
have  been  found:  protein  kinase  C,12 p44  MAP
kinase  (also  named  ERK1),  p42  MAP  kinase  (also
named ERK2)13–15 and p38 MAP kinase.16 The aim of
our present work was to investigate, which of them
are  involved  in  the  TPA-induced  arachidonic  acid
release  in  bovine  platelets  by  using  specific  inhibi-
tors of the protein kinases.
Materials and Methods
Reagents
MAFP  (methyl  arachidonylfluorophosphonate),  BEL
((E)-6-(bromomethylidene)-3-(1-naphthyl)-3,4,5,6-tet-
rahydro-2H-pyran-2-one),  RHC  80267  (1,6-bis(cyclo-
hexyloximinocarbonylamino)hexane),  PD  98059
(29 -amino-39 -methoxyflavone),  12-O-tetradecanoyl-
phorbol-13-acetate  (TPA)  (Biomol,  Hamburg);  SB
202190  (4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-
5-(4-pyridyl)-1H-imidazole),  GF  109203X  (2-[1-(3-di-
methylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl)
maleimide),  Ro  31–8220  (2-{1-[3-(Amidinothio)pro-
pyl]-1H-indol-3-yl}-3-(1-methyl-1H-indole-3-yl)malei-
mide  methane  sulphonate)  (Calbiochem,  Bad
Soden);  5,8,11,14-eicosatetraynoic  acid  (ETYA),
staurosporine,  calcium  ionophore  A23187,  arachi-
donic acid, phosphate buffered saline tablets (Sigma,
Deisenhofen);  EDTA-Na2,  dimethyl  sulphoxide
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Mediators of Inflammation, 9, 31–34 (2000)(DMSO) (Merck, Darmstadt), ML 3116 (1-(7-carboxy-
heptyl)-3-dodecanoyl-1H-indole-2-carboxylic  acid)
was  synthesized  by  the  published  procedure;17
bovine blood (local slaughterhouse).
Cells
Immediately  after  the  death  of  the  animal,  bovine
blood (1 litre) was collected in a polypropylene vessel
containing  a  solution  of  0.077 M EDTA-Na2 in  0.2%
(w /v) saline (0.1 litre per 1 litre blood). After dilution
of the blood with 0.5 litre of 0.9% (w /v) saline the
platelets were isolated by centrifugation as previously
described.18 The  platelets  were  stored  at  +4°C. All
experiments  were  performed  within  8 h  after  isola-
tion of the platelets.
Measurement of inhibition of cPLA2-activity
Inhibition of cPLA2 was determined by measuring the
TPA-  or  calcium  ionophore A23187-induced  arachi-
donic acid release from bovine platelets with HPLC/
UV-detection as previously described.11,18 Briefly, to a
solution of ETYA in DMSO, which inhibits formation
of  arachidonic  acid  metabolites  in  platelets,  was
added  the  DMSO  solution  of  a  test  compound  or
DMSO  alone  (in  case  of  the  control  tests  and  the
kinetic experiments) followed by the platelet suspen-
sion and a solution of calcium chloride at 37°C (final
platelet concentration: about 8 ´ 108 cells/2 ml). Then
the  cPLA2 was  activated  by TPA  (2 m M)  or A23187
(20 m M). The  solution  of TPA  was  freshly  prepared
each time. When using TPA as stimulant the incuba-
tion  time  was  variable  (kinetic  experiments)  or
60 min (experiments with enzyme inhibitors). In the
experiments  with A23187  the  incubation  time  was
1 min.  After  terminating  the  enzyme  reaction  the
produced arachidonic acid was cleaned up by solid-
phase extraction and quantified with HPLC/UV-detec-
tion at 200 nm.
Solubility of the test compounds
All  compounds  were  soluble  under  the  test
conditions.
Cell lytic potency of the test compounds
The  cell  lytic  potency  of  the  test  compounds  was
measured by turbidimetry according to a procedure
previously described.19 The compounds did not show
cell lytic properties at the concentrations applied.
Results
Recently, we  have reported  that TPA  stimulates the
liberation  of  arachidonic  acid  in  washed  bovine
platelets.11 The  time  course  of  arachidonic  acid
release  was  sigmoid  reaching  a  plateau  after  about
15 min. To avoid metabolism of arachidonic acid via
the cyclooxygenase-1 and the 12-lipoxygenase path-
ways,  the  dual  cyclooxygenase-1/12-lipoxygenase-
inhibitor 5,8,11,14-eicosatetraynoic acid (ETYA) was
added to the platelets in these experiments. We now
have  found  that  a  second  even  more  pronounced
arachidonic acid liberation  occurs if  the incubation
was extended (Fig. 1). However, this second step of
arachidonic  acid  release  only  could  be  measured
when fresh (1–2 days old) platelets were used, while
the first step still appeared 3–4 days after the isolation
of the platelets from bovine blood.
Contribution of the cPLA2 to the arachidonic
acid release in TPA-treated platelets
The arachidonic acid release in A23184-treated plate-
lets is catalysed by group IV cytosolic phospholipase
A2 (cPLA2 ).20–23 To investigate, whether cPLA2 is also
predominantly  responsible  for  the  arachidonic  acid
liberation induced by TPA, we monitored the inhibi-
tion of the whole arachidonic acid production after
TPA stimulation (incubation time 60 min) by several
PLA2 inhibitors.  Methyl  arachidonyfluorophospho-
nate (MAFP),24,25 which is known as dual inhibitor of
cPLA2 and group VI Ca2+-independent phospholipase
A2 (iPLA2 ),26 blocked the arachidonic release to about
82%  at  10 m M  (Table  1).  Experiments  with  higher
MAFP concentrations have not been performed, since
we had found that MAFP shows cytotoxic properties
at concentrations not far above 10 m M. So a significant
loss of lactate dehydrogenase from the cells could be
determined at 33 m M.19
A recent study has demonstrated that both cPLA2
and iPLA2 are involved in protein kinase dependent
arachidonic  acid  liberation  in  macrophage-like
P388D1 cells.27 Therefore,  we  also  examined  the
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FIG. 1. Kinetics of the release of arachidonic acid by bovine
platelets (8 ´ 10
8 cells/2ml) after stimulation with TPA (2 m M)
in  the  presence  of  the  dual  cyclooxygenase–1/12-lipoxy-
genase-inhibitor  ETYA  (10 m M),  which  inhibits  the  further
metabolization of arachidonic acid to thromboxane B2 and
12-HETE.effect  of  the  selective  iPLA2 inhibitor  bromoenol
lactone  (BEL)  on  TPA-induced  arachidonic  acid
release. At a concentration  of 5 m M BEL, at which a
maximal  effect  on  iPLA2–activity  has  been  ascer-
tained,27 the  arachidonic  acid  liberation  was
decreased by about 27%. On the other hand, with the
cPLA2 inhibitor ML 3116,28 which is able to block the
arachidonic acid release in A23187-stimulated plate-
lets  nearly  completely,  the TPA-induced  arachidonic
acid liberation could only be inhibited to about 70%.
The increase of ML 3116 concentration from 10 m M to
33 m M did not cause a further decrease of arachidonic
acid release.
Recently it was suggested, that in rat liver macro-
phages TPA leads to an arachidonic acid release via an
activation  of  PLC  and  DAG  lipase.29 If  at  all,  in
platelets this  pathway  does not  play  a  greater  role,
since the arachidonic acid formation was not affected
by the DAG  lipase inhibitor RHC 80267 (concentra-
tion: 100 m M).
In conclusion, we propose that two different PLA2s,
cPLA2 and  iPLA2,  are  mainly  responsible  for  the
liberation of arachidonic acid from platelet phospho-
lipids after stimulation with TPA.
Effect of protein kinase inhibitors on the
TPA-induced liberation of arachidonic acid in
platelets
To investigate the role of the different protein kinases
present  in  platelets  on  the TPA-induced  phospholi-
pase A2 activation, we measured the inhibition of the
arachidonic  acid  formation  by  the  potent  broad
spectrum protein kinase inhibitor staurosporine, the
PKC  inhibitors  GF  109203X  and  Ro  31–8220,  the
p44/p42 MAP kinase inhibitor PD 98059 and the p38
MAP kinase inhibitor SB 202190. The inhibitors were
applied at concentrations, at which a full inhibition of
the appropriate protein kinase had been achieved in
intact  cells  according  to  data  in  the
literature.6,7,30–33
Staurosporine  strongly  inhibited  arachidonic  acid
formation  (Table  1).  Similar  results  were  obtained
with  the  PKC  inhibitors  GF  109203X  and  Ro
31–8220, and with the p38 MAP kinase inhibitor SB
202190. However, their inhibition values were a little
bit lower than that of staurosporine. In contrast, the
p42/44 MAP kinase inhibitor PD 98059 exhibited only
a  weak  inhibition  of  the  arachidonic  acid  release
(about 26% at 33 m M).
Effect of the protein kinase inhibitors on the
A23187-induced liberation of arachidonic acid
in platelets
Staurosporine, GF 109203X, Ro 31–8220, SB 202190
and  PD  98059  did  not  inhibit  the  arachidonic  acid
release in A23187-stimulated  bovine platelets at  the
concentrations applied in the experiments with TPA,
thus protein kinases do not seem to be involved in the
A23187-induced arachidonic acid liberation. The inef-
fectiveness  of  the  DAG  lipase  inhibitor  RHC  80267
(concentration 100 m M) in these experiments confirm
the results of previous studies, which demonstrated
that the PLC/DAG  lipase pathway is not involved in
the  arachidonic  acid  liberation  occurring  after  the
stimulation of platelets with A23187.20,22
Discussion
The  experiments  with  the  PLA2 inhibitors  propose
that cPLA2 and to a lesser extent iPLA2 are responsible
for the TPA-induced arachidonic acid release in bovine
platelets.
As far as the applied protein kinase inhibitors have
the specificity ascribed in literature, the pronounced
inhibition of TPA-induced arachidonic acid release by
the PKC inhibitors GF 109203X and Ro 31-8220 and
by the p38 MAP kinase inhibitor SB 202190 suggests
that the activation of the PLA2s in platelets by TPA is
mediated via an activation of PKC and the p38 MAP
kinase.  Although  the  effect  of  PD  98059  on  TPA-
induced arachidonic acid release was significantly less
pronounced  than  that  of  the  other  protein  kinase
inhibitors investigated, p42/p44 MAP kinase may also
be involved in the activation of the PLA2s.
In  conclusion,  the  results  indicate  that  the TPA-
induced  arachidonic  acid  liberation  is  mediated  via
other mechanisms than the arachidonic acid release
observed  after  stimulation  with  A23187.  Further
investigations  will  be  necessary  to  elucidate  the
Effects of protein kinases and phospholipases A2 on arachidonic and liberation
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Table 1. Effect of the PLA2 inhibitors MAFP, ML 3116 and BEL,
the DAG  lipase inhibitor  RHC  80267 and  different  protein
kinase inhibitors on the TPA- and A23187-induced release of
arachidonic acid in bovine platelets








MAFP (10 m M) 82 ± 5 61 ± 5
ML 3116 (10 m M) 66 ± 3 82 ± 2
(33 m M) 70 ± 2 94 ± 3
BEL (5 m M) 27 ± 13 NS
b




Staurosporine (1 m M) 92 ± 6 NS
b
GF 109203X (10 m M) 89 ± 1 NS
b
Ro 31–8220 (5 m M) 78 ± 2 NS
b
SB 202190 (33 m M) 73 ± 16 NS
b
PD 98059 (33 m M) 26 ± 3 NS
b
a Means ± SD, n = 3; in the case of SB 202190 and PD 98059, n = 4; in
the case of BEL, n = 6.
b NS, not significant.sequence of  the events occurring after TPA-stimula-
tion and the reasons for the biphasic arachidonic acid
liberation observed.
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